Tocagen Inc. (NASDAQ:TOCA) spotted trading -21.58% off 52-week high price. On the other end, the stock has been noted 64.76% away from the low price over the last 52-weeks. The stock changed 0.41% to recent value of $12.39. The stock transacted 102210 shares during most recent day however it has an average volume of 272.21K shares. The company has 19.95M of outstanding shares and 18.26M shares were floated in the market.
Tocagen Inc. (NASDAQ:TOCA), a clinical-stage, cancer-selective gene therapy company, = announced that Lori Kunkel, M.D. has been named acting chief medical officer, effective November 26, 2018. Asha Das, M.D., senior vice president and chief medical officer will be leaving the company effective November 23, 2018 to allow her to focus on unforeseen and immediate personal matters. The company has initiated a search process to fill the position.
“On behalf of the management team and Board of Directors, we are thankful for the significant contributions Asha has made over the past three years,” said Marty J. Duvall, chief executive officer of Tocagen. “With Lori’s remarkable track record in the biotechnology industry coupled with her deep familiarity of our program and clinical data we look forward to working closely with her to advance our cancer-selective gene therapy platform, and our lead product candidate. This transition is not expected to impact our current business plans or development timelines.”
Among other responsibilities, Dr. Kunkel previously served as acting chief medical officer of Loxo Oncology, Inc, chief medical officer of Pharmacyclics LLC, acquired by AbbVie Inc., and chief medical officer of Proteolix, Inc., acquired by Onyx Pharmaceuticals. Dr. Kunkel currently serves on the board of directors of Loxo Oncology, Inc., a publicly held biotechnology company, Curis, Inc., a publicly held biotechnology company, and Maverick Therapeutics, Inc., a privately held biotechnology company. A full biography is available here. In connection with Dr. Kunkel’s appointment as acting chief medical officer of Tocagen, Dr. Kunkel will be temporarily leaving the board of directors of Tocagen in order for the company to maintain compliance with the Nasdaq listing rules regarding independent directors.
“Being dedicated to the development of new treatment options for patients with brain cancer, I am extremely grateful to have worked closely with the Tocagen team on advancing Toca 511 & Toca FC and regret having to leave the company at this time,” said Dr. Das. “I am excited about the potential of the Toca 5 trial and future development in newly diagnosed brain cancer to positively impact patients around the world.”
Its earnings per share (EPS) expected to touch remained -47.30% for this year. According to the most recent quarter its current ratio was 5.8 that represents company’s ability to meet its current financial obligations. The price moved ahead of 8.12% from the mean of 20 days, -0.42% from mean of 50 days SMA and performed 14.93% from mean of 200 days price. Company’s performance for the week was -5.28%, -2.21% for month and YTD performance remained 20.88%.
Sebastian Power also covers the financial news across all market sectors. He also has an enormous knowledge of stock market. Sebastian holds an MBA degree from University of Florida. He has more than 10 years of experience in writing financial and market news. He previously worked at a number of companies in different role including web developer, software engineer and product manager. He currently covers financial news section for our site.
Address: 4658 Columbia Road, Wrangle Hill, Delaware
Phone number: 302-838-9976
Email: [email protected]